Eleva开始对治疗罕见肾病的新药进行人体试验 并任命新的CFO Eleva starts human trials for a new drug treating a rare kidney disease and appoints a new CFO.

Eleva是一家生物制药公司,它已开始对一种新药CPV-104进行首次人类试验,旨在治疗一种罕见的肾病C3-Glomerulopathy。 Eleva, a biopharmaceutical company, has begun its first human trials for a new drug, CPV-104, aimed at treating C3-Glomerulopathy, a rare kidney disease. 该药物旨在恢复身体补充系统内部的平衡。 The drug aims to restore balance within the body's complement system. 此外,Eleva已任命Donato Spota为新的首席财务官,帮助管理该公司在临床研究进展过程中的财务战略。 Additionally, Eleva has appointed Donato Spota as its new Chief Financial Officer to help manage the company's financial strategies as it progresses with its clinical studies.